Biotech and pharma companies invest significant resources in the presentation and promotion of their data at medical conferences. This is because wider appreciation of their promising experimental drugs should bring collaborations with bigger partners and interest from investors. However, for two companies the recent European Hematology Association (EHA) conference was the equivalent of an ‘anti-conference’ where their data presentations would have deterred investor and partnering interest.
On the positive side, the release of more detailed data on Gilead Sciences, Inc.’s anti-CD47 antibody magrolimab in hematological...
